Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “market perform” rating reaffirmed by equities researchers at Sanford C. Bernstein in a research report issued on Thursday. They currently have a GBX 4,311 ($71.54) price target on the stock. Sanford C. Bernstein’s price objective would suggest a potential downside of 5.81% from the stock’s previous close.

A number of other analysts have also recently weighed in on AZN. Analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. They now have a GBX 4,400 ($73.02) price target on the stock. Separately, analysts at Bryan Garnier & Cie reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 28th. They now have a GBX 4,400 ($73.02) price target on the stock. Six research analysts have rated the stock with a sell rating, seventeen have given a hold rating and six have assigned a buy rating to the stock. AstraZeneca plc currently has an average rating of “Hold” and an average price target of GBX 4,058.72 ($67.35).

AstraZeneca plc (LON:AZN) opened at 4562.00 on Thursday. AstraZeneca plc has a 1-year low of GBX 3086.50 and a 1-year high of GBX 5750.00. The stock’s 50-day moving average is GBX 4339.85 and its 200-day moving average is GBX 4245.93. The company’s market cap is £57.618 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.